MYGN Stock Gains Following the Launch of Know More Sooner

Company Overview - Myriad Genetics, Inc. (MYGN) has launched a new educational website, Know More Sooner, aimed at providing comprehensive information about reproductive and prenatal genetic testing, which is expected to enhance the company's Prenatal business [1][5] - The company currently has a market capitalization of $937.2 million and has consistently surpassed earnings estimates in the past four quarters, with an average surprise of 247.73% [4] Stock Performance - Following the launch of the Know More Sooner website, MYGN shares increased by 3.9%, reaching $12.76 [2] - Over the past year, MYGN's shares have declined by 42.2%, in contrast to a 12.4% decline in the industry [10] Market Insights - A survey indicated that a majority of women expressed interest in prenatal screening once they understood the benefits of genetic testing, although 40% reported not being offered non-invasive prenatal testing (NIPT) [3] - The global non-invasive prenatal testing market was valued at $4.21 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.06% from 2024 to 2030, driven by increasing demand, collaborations, and improved reimbursement scenarios [7] Product Offerings - Myriad Genetics offers three genetic tests for pregnant individuals: the SneakPeek Gender Test, which predicts fetal sex with over 99% accuracy as early as six weeks; the Foresight Carrier Screen, which identifies risks for serious inherited conditions; and the Prequel Prenatal Screen, which assesses risks for various chromosomal conditions as early as eight weeks [6]